Alx Oncology Holdings Inc (ALXO) Stock Price, Quote & News

Company Profile

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 466 7125

Website: www.alxoncology.com

Address:

323 Allerton Avenue, South San Francisco, United States

MakingMoneyHere Dec. 4 at 1:31 PM

$ALXO sounds good https://pharmashots.com/29880/evorpacepts-momentum-in-her2-gastric-cancer-a-conversation-with-jason-lettmann-from-alx-oncology/

0 · Reply

MakingMoneyHere Dec. 3 at 7:20 PM

$ALXO Okey 2,20$ again... but more?

0 · Reply

StarLord13 Dec. 2 at 10:08 PM

$ALXO Only good news is this is very oversold on the hourly time frame and should see a bounce then I’m out.

0 · Reply

Wizzard88 Dec. 2 at 9:30 PM

$ALXO I should sell this shit last week !! Although I was still in loss ! But not now !!!

0 · Reply

Wizzard88 Dec. 2 at 9:29 PM

$ALXO Why this turd digging ???

0 · Reply

StarLord13 Dec. 2 at 7:59 PM

$ALXO Going under a dollar by Friday if the rest of the week is anything like these past 2 days 🤦‍♂️

0 · Reply

StarLord13 Dec. 1 at 8:42 PM

$ALXO Shorts keep bringing this down non stop one penny at a time. Same show now every day.

1 · Reply

StarLord13 Dec. 1 at 8:20 PM

$ALXO Red when market is green. Red when market is red. If this breaks 1.29 it’s over.

0 · Reply

MakingMoneyHere Nov. 28 at 4:45 PM

$ALXO Every time the stupid CEO comes out and says something, the stock drops by at least 100%

0 · Reply

StarLord13 Nov. 26 at 8:10 PM

$ALXO Why are all my other bios ripping today and this one is dripping?

0 · Reply

ALX Oncology to Present at Upcoming Investor Conferences

Nov 7, 2025, 3:56 PM EST - 27 days ago

ALX Oncology Holdings Inc. (ALXO) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 8:15 AM EST - 4 weeks ago

ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 30, 2025, 8:30 AM EDT - 5 weeks ago

ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting

Oct 23, 2025, 12:30 PM EDT - 6 weeks ago

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

Oct 3, 2025, 9:05 AM EDT - 2 months ago

ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 12, 2025, 8:30 AM EDT - 3 months ago

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

Aug 29, 2025, 12:00 PM EDT - 3 months ago

ALX Oncology to Participate in Upcoming Investor Conferences in September

Aug 19, 2025, 8:00 AM EDT - 3 months ago

ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors

Aug 12, 2025, 9:45 PM EDT - 4 months ago

ALX Oncology Holdings Inc. (ALXO) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 4 months ago

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 5, 2025, 8:00 AM EDT - 4 months ago

ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025

May 30, 2025, 8:00 AM EDT - 6 months ago

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

May 20, 2025, 8:00 AM EDT - 7 months ago

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

May 13, 2025, 8:00 AM EDT - 7 months ago

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

May 8, 2025, 8:30 AM EDT - 7 months ago

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 2, 2025, 8:00 AM EDT - 7 months ago

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 25, 2025, 1:10 PM EDT - 7 months ago

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

Apr 25, 2025, 9:00 AM EDT - 8 months ago

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

Mar 6, 2025, 4:01 PM EST - 9 months ago

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 5, 2025, 8:00 AM EST - 9 months ago

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

Feb 27, 2025, 8:00 AM EST - 10 months ago

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 18, 2025, 8:00 AM EST - 10 months ago

ALX Oncology to Host Virtual R&D Day on March 5, 2025

Jan 23, 2025, 8:00 AM EST - 11 months ago

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

Jan 22, 2025, 4:01 PM EST - 11 months ago

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

Jan 21, 2025, 5:00 PM EST - 11 months ago

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

Dec 18, 2024, 8:00 AM EST - 1 year ago

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

Nov 14, 2024, 8:00 AM EST - 1 year ago

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

Nov 7, 2024, 4:00 PM EST - 1 year ago

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 1, 2024, 5:30 PM EDT - 1 year ago

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

Sep 11, 2024, 10:36 PM EDT - 1 year ago

ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations

Aug 6, 2024, 4:01 PM EDT - 1 year ago

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

Jul 31, 2024, 4:01 PM EDT - 1 year ago

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

Jul 31, 2024, 5:30 AM EDT - 1 year ago

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Jun 27, 2024, 4:13 AM EDT - 1 year ago

ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation

Jun 2, 2024, 10:00 AM EDT - 1 year ago

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

May 29, 2024, 9:00 AM EDT - 1 year ago

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

May 9, 2024, 4:00 PM EDT - 1 year ago

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 9:00 AM EDT - 1 year ago

ALX Oncology Appoints Allison Dillon as Chief Business Officer

Apr 24, 2024, 10:00 AM EDT - 1 year ago

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

$ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)$

Apr 9, 2024, 5:30 PM EDT - 1 year ago

ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)

Mar 7, 2024, 4:03 PM EST - 1 year ago

ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 5, 2024, 4:30 PM EST - 1 year ago

ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting

Dec 8, 2023, 8:30 AM EST - 2 years ago

ALX Oncology shares jump 9% after Jefferies upgrade

Nov 13, 2023, 4:05 PM EST - 2 years ago

ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 10, 2023, 4:05 PM EDT - 2 years ago

ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 9, 2023, 12:38 AM EDT - 2 years ago

ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept

Oct 5, 2023, 8:00 AM EDT - 2 years ago

ALX Oncology Announces Pricing of Public Offering

Oct 4, 2023, 4:10 PM EDT - 2 years ago

ALX Oncology Announces Proposed Public Offering

Oct 3, 2023, 11:15 AM EDT - 2 years ago

Why ALX Oncology Stock Is Skyrocketing Today

MakingMoneyHere Dec. 4 at 1:31 PM

$ALXO sounds good https://pharmashots.com/29880/evorpacepts-momentum-in-her2-gastric-cancer-a-conversation-with-jason-lettmann-from-alx-oncology/

0 · Reply

MakingMoneyHere Dec. 3 at 7:20 PM

$ALXO Okey 2,20$ again... but more?

0 · Reply

StarLord13 Dec. 2 at 10:08 PM

$ALXO Only good news is this is very oversold on the hourly time frame and should see a bounce then I’m out.

0 · Reply

Wizzard88 Dec. 2 at 9:30 PM

$ALXO I should sell this shit last week !! Although I was still in loss ! But not now !!!

0 · Reply

Wizzard88 Dec. 2 at 9:29 PM

$ALXO Why this turd digging ???

0 · Reply

StarLord13 Dec. 2 at 7:59 PM

$ALXO Going under a dollar by Friday if the rest of the week is anything like these past 2 days 🤦‍♂️

0 · Reply

StarLord13 Dec. 1 at 8:42 PM

$ALXO Shorts keep bringing this down non stop one penny at a time. Same show now every day.

1 · Reply

StarLord13 Dec. 1 at 8:20 PM

$ALXO Red when market is green. Red when market is red. If this breaks 1.29 it’s over.

0 · Reply

MakingMoneyHere Nov. 28 at 4:45 PM

$ALXO Every time the stupid CEO comes out and says something, the stock drops by at least 100%

0 · Reply

StarLord13 Nov. 26 at 8:10 PM

$ALXO Why are all my other bios ripping today and this one is dripping?

0 · Reply

Iorgi Nov. 21 at 8:49 PM

$ALXO Someone is sending us a strong message with ALXO. This might be very rewarding.

1 · Reply

LudicrousReturns Nov. 19 at 3:53 AM

18 NOV 2025 Ludicrous Returns Stock Model Update Sell Now: CSIQ, VECO (Stop Sell) price of Monday buys: IDAI (4.14), IRWD (2.46), QNRX (14.14), PALI (1.56), REGN (595.53), SHIP (7.96), SPRU (4.37) Updated Stop Sell: AMD (220.49) Buy Now: $ALXO, $DHR, $LAR Two buys with big growth potential that are very close to buy trigger: BIIB, VRA

0 · Reply

P119 Nov. 17 at 7:34 PM

$ALXO don’t spam other tickers

0 · Reply

superyin Nov. 17 at 7:03 PM

$TLRY I still believe this ticker mimics the movement in $ALXO in many ways—I think we will soon see a 10-15% climb on no news and that will be the bull signal for a brief run-up back to previous support levels—I don't think we're going to retest 80 cents, but 60 and 90 cents possibly—I am hoping volatility returns to this sector, though, because we have volume and I think even without news, an increase of macro activity could help this thing edge up before any real catalysts and that will be my signal of the return to bull trend

1 · Reply

StarLord13 Nov. 17 at 4:43 PM

$ALXO Let’s see if we can crack that orange MA.

0 · Reply

StarLord13 Nov. 14 at 9:01 PM

$ALXO Nice start to the weekend.

0 · Reply

GoImugene Nov. 14 at 5:16 PM

$ALXO high expectations for this Phase 2 clinical trial result to complete in March of next year. Phase 1 results were spectacular. https://clinicaltrials.gov/study/NCT05025800

0 · Reply

StarLord13 Nov. 14 at 4:33 PM

$ALXO Up 20% today on no news. My price avrg is right at this level. To sell and buy more on any drop or to hold 🤔

2 · Reply

Wizzard88 Nov. 14 at 4:31 PM

$ALXO Do not tag other tickers here ! Keep it silent 🤫

0 · Reply

StarLord13 Nov. 14 at 2:44 PM

$ALXO only green on my watch list👀

1 · Reply

BillionerOfKing Nov. 11 at 12:12 PM

$ALXO Current Stock Price: $1.27 Contracts to trade: $0.5 ALXO Nov 21 2025 Call Entry: $1.22 Exit: $2.43 ROI: 100% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

P119 Nov. 7 at 9:45 PM

$ALXO 2+ by end of this month

0 · Reply

Market Cap	65.06M
Revenue (ttm)	0.00
Net Income (ttm)	-134.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.23

Volume	147,600
Avg Vol	463,150
Day's Range	N/A - N/A
Shares Out	54.22M
Stochastic %K	33%
Beta	0.53
Analysts	Strong Sell
Price Target	$2.50